{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:12:48Z","timestamp":1780344768054,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There are limited data describing adverse infant outcomes in infants born to women with a low risk of complications during pregnancy, such as those who may be enrolled in maternal immunization trials. This retrospective study estimated incidence proportions of infant outcomes in different cohorts of liveborn infants in England between 2005 and 2017.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The incidence proportions of 10 infant outcomes were calculated for liveborn infants from pregnancies represented in the Clinical Practice Research Datalink (CPRD) Mother-Baby Link (MBL) and linkage to Hospital Episode Statistics (HES). Three infant cohorts were designed: (1) the all pregnancies infants cohort (<jats:italic>N<\/jats:italic>\u2009=\u2009185,119), (2) the all pregnancies with a gestational age (GA)\u2009\u2265\u200924\u00a0weeks infants cohort (<jats:italic>N<\/jats:italic>\u2009=\u2009183,869), and (3) the low-risk pregnancies infants cohort (LR infants cohort, <jats:italic>N<\/jats:italic>\u2009=\u2009121,871), which included pregnancies with a GA\u2009\u2265\u200924\u00a0weeks and no diagnosis of predefined high-risk medical conditions until 24\u00a0weeks GA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The most common adverse infant outcome in the three infant cohorts was macrosomia (e.g., 1,085.9\/10,000 live births in the LR infants cohort), followed by minor congenital anomalies (e.g., 800.6\/10,000 in the LR infants cohort), very low\/low birth weight (e.g., 400.6\/10,000 in the LR infants cohort), and major congenital anomalies (e.g., 270.4\/10,000 in the LR infants cohort). The incidence proportions for early-onset sepsis, very low\/low birth weight, and minor and major congenital anomalies were lower in the LR infants than in the other cohorts (non-overlapping confidence intervals [CIs]). The incidence proportions of neonatal death, infant death, late-onset sepsis, macrosomia, small for GA, and large for GA were similar between cohorts (overlapping CIs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study generated background rates of adverse infant outcomes from liveborn infants of all and low-risk pregnancies represented in the CPRD Pregnancy Register MBL and linkage to HES. The results indicate lower incidence proportions of several adverse infant outcomes in infants from low-risk pregnancies compared to all pregnancies, illustrating the importance of considering maternal risk factors. These background rates may facilitate the interpretation of safety data from maternal immunization trials and of pharmacovigilance data from maternal vaccines. They may also be of interest for other interventions studied in pregnant women.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-023-05598-2","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T07:31:40Z","timestamp":1683703900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adverse infant outcomes following low-risk pregnancies in England: a retrospective cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Megan","family":"Riley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Lambrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouzama","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Sawalhi-Leckenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia K.","family":"Stoszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"issue":"4","key":"5598_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/21645515.2015.1127485","volume":"12","author":"H Marshall","year":"2016","unstructured":"Marshall H, McMillan M, Andrews RM, Macartney K, Edwards K. Vaccines in pregnancy: The dual benefit for pregnant women and infants. Hum Vaccin Immunother. 2016;12(4):848\u201356.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"5598_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/07853890.2017.1421320","volume":"50","author":"I Vojtek","year":"2018","unstructured":"Vojtek I, Dieussaert I, Doherty TM, Franck V, Hanssens L, Miller J, et al. Maternal immunization: where are we now and how to move forward? Ann Med. 2018;50(3):193\u2013208.","journal-title":"Ann Med"},{"issue":"13","key":"5598_CR3","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra1509044","volume":"376","author":"SB Omer","year":"2017","unstructured":"Omer SB. Maternal Immunization. N Engl J Med. 2017;376(13):1256\u201367.","journal-title":"N Engl J Med"},{"key":"5598_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3389\/fimmu.2018.00436","volume":"9","author":"FM Munoz","year":"2018","unstructured":"Munoz FM. Current Challenges and Achievements in Maternal Immunization Research. Front Immunol. 2018;9:436.","journal-title":"Front Immunol"},{"issue":"49","key":"5598_CR5","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1016\/j.vaccine.2016.07.006","volume":"34","author":"J Bonhoeffer","year":"2016","unstructured":"Bonhoeffer J, Kochhar S, Hirschfeld S, Heath PT, Jones CE, Bauwens J, et al. Global alignment of immunization safety assessment in pregnancy - The GAIA project. Vaccine. 2016;34(49):5993\u20137.","journal-title":"Vaccine"},{"issue":"2","key":"5598_CR6","doi-asserted-by":"publisher","first-page":"e56583","DOI":"10.1371\/journal.pone.0056583","volume":"8","author":"LC Kenny","year":"2013","unstructured":"Kenny LC, Lavender T, McNamee R, O\u2019Neill SM, Mills T, Khashan AS. Advanced maternal age and adverse pregnancy outcome: evidence from a large contemporary cohort. PLoS ONE. 2013;8(2):e56583.","journal-title":"PLoS ONE"},{"key":"5598_CR7","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.5888\/pcd12.150362","volume":"12","author":"SY Kim","year":"2015","unstructured":"Kim SY, Kotelchuck M, Wilson HG, Diop H, Shapiro-Mendoza CK, England LJ. Prevalence of adverse pregnancy outcomes, by maternal diabetes status at first and second deliveries, Massachusetts, 1998\u20132007. Prev Chronic Dis. 2015;12:E218.","journal-title":"Prev Chronic Dis"},{"issue":"10","key":"5598_CR8","doi-asserted-by":"publisher","first-page":"e0186287","DOI":"10.1371\/journal.pone.0186287","volume":"12","author":"SC Lean","year":"2017","unstructured":"Lean SC, Derricott H, Jones RL, Heazell AEP. Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. PLoS ONE. 2017;12(10):e0186287.","journal-title":"PLoS ONE"},{"issue":"3","key":"5598_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/14767050903550659","volume":"23","author":"EA Reece","year":"2010","unstructured":"Reece EA. The fetal and maternal consequences of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2010;23(3):199\u2013203.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"5598_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s12884-022-04769-x","volume":"22","author":"M Riley","year":"2022","unstructured":"Riley M, Lambrelli D, Graham S, Henry O, Sutherland A, Schmidt A, et al. Facilitating safety evaluation in maternal immunization trials: a retrospective cohort study to assess pregnancy outcomes and events of interest in low-risk pregnancies in England. BMC Pregnancy Childbirth. 2022;22(1):461.","journal-title":"BMC Pregnancy Childbirth"},{"key":"5598_CR11","unstructured":"Clinical Practice Research Datalink (CPRD). Pregnancy Register and Mother-baby link. https:\/\/cprd.com\/linked-data#Mother-baby%20link%20and%20Pregnancy%20Register. Accessed 9 June 2021."},{"issue":"7","key":"5598_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/pds.4811","volume":"28","author":"C Minassian","year":"2019","unstructured":"Minassian C, Williams R, Meeraus WH, Smeeth L, Campbell OMR, Thomas SL. Methods to generate and validate a pregnancy register in the UK clinical practice research datalink primary care database. Pharmacoepidemiol Drug Saf. 2019;28(7):923\u201333.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5598_CR13","unstructured":"Clinical Practice Research Datalink (CPRD). https:\/\/cprd.com\/home. Accessed 9 June 2021."},{"issue":"3","key":"5598_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.","journal-title":"Int J Epidemiol"},{"key":"5598_CR15","unstructured":"Clinical Practice Research Datalink (CPRD). CPRD linked data. https:\/\/www.cprd.com\/linked-data. Accessed 9 June 2021."},{"issue":"2","key":"5598_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/AOG.0000000000001190","volume":"127","author":"GG Donders","year":"2016","unstructured":"Donders GG, Halperin SA, Devlieger R, Baker S, Forte P, Wittke F, et al. Maternal immunization with an investigational trivalent group B streptococcal vaccine: A randomized controlled trial. Obstet Gynecol. 2016;127(2):213\u201321.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"5598_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1473-3099(15)00484-3","volume":"16","author":"RS Heyderman","year":"2016","unstructured":"Heyderman RS, Madhi SA, French N, Cutland C, Ngwira B, Kayambo D, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis. 2016;16(5):546\u201355.","journal-title":"Lancet Infect Dis"},{"issue":"44","key":"5598_CR18","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.1016\/j.vaccine.2020.08.056","volume":"38","author":"GK Swamy","year":"2020","unstructured":"Swamy GK, Metz TD, Edwards KM, Soper DE, Beigi RH, Campbell JD, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial. Vaccine. 2020;38(44):6930\u201340.","journal-title":"Vaccine"},{"issue":"7","key":"5598_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/14760584.2020.1791092","volume":"19","author":"W Kandeil","year":"2020","unstructured":"Kandeil W, van den Ende C, Bunge EM, Jenkins VA, Ceregido MA, Guignard A. A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis. Expert Rev Vaccines. 2020;19(7):621\u201338.","journal-title":"Expert Rev Vaccines"},{"issue":"49","key":"5598_CR20","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1016\/j.vaccine.2016.07.007","volume":"34","author":"CE Jones","year":"2016","unstructured":"Jones CE, Munoz FM, Kochhar S, Vergnano S, Cutland CL, Steinhoff M, et al. Guidance for the collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy. Vaccine. 2016;34(49):6007\u201314.","journal-title":"Vaccine"},{"key":"5598_CR21","unstructured":"EUROCAT. EUROCAT Guide 1.4 and Reference Documents. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/data-collection\/guidelines-for-data-registration_en. Accessed 9 June 2021."},{"issue":"49","key":"5598_CR22","doi-asserted-by":"publisher","first-page":"6015","DOI":"10.1016\/j.vaccine.2016.03.047","volume":"34","author":"M DeSilva","year":"2016","unstructured":"DeSilva M, Munoz FM, McMillan M, Kawai AT, Marshall H, Macartney KK, et al. Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016;34(49):6015\u201326.","journal-title":"Vaccine"},{"key":"5598_CR23","unstructured":"Office for National Statistics. Birth characteristics, 2016 workbook, Table 5. Live births (numbers and percentages): birthweight and area of usual residence, 2016. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/livebirths\/datasets\/birthcharacteristicsinenglandandwales. Accessed 9 June 2021."},{"key":"5598_CR24","unstructured":"Public Health England. National Congenital Anomaly and Rare Disease Registration Service: Congenital anomaly statistics 2016. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/751553\/Congenital_anomaly_statistics_2016.pdf. Accessed 9 June 2021."},{"key":"5598_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-90-481-9485-8_20","volume":"686","author":"H Dolk","year":"2010","unstructured":"Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010;686:349\u201364.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"5598_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/pubmed\/fdaa025","volume":"43","author":"S Nath","year":"2021","unstructured":"Nath S, Hardelid P, Zylbersztejn A. Are infant mortality rates increasing in England? The effect of extreme prematurity and early neonatal deaths. J Public Health (Oxf). 2021;43(3):541\u201350.","journal-title":"J Public Health (Oxf)"},{"issue":"4","key":"5598_CR27","first-page":"133","volume":"12","author":"G Watson","year":"2016","unstructured":"Watson G, Caldwell C, Kennea N. Neonatal early onset sepsis: a reflection on the NICE guidance. Infant. 2016;12(4):133\u20135.","journal-title":"Infant"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-023-05598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-023-05598-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-023-05598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T07:45:31Z","timestamp":1683704731000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-023-05598-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5598"],"URL":"https:\/\/doi.org\/10.1186\/s12884-023-05598-2","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"7 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CPRD obtained ethics approval to receive and supply patient data for public health research (). The protocol of this retrospective observational cohort study was approved by the Independent Scientific Advisory Committee (ISAC) for research involving CPRD data (protocol no. 18_144RA) and has been made available to the journal reviewers. All methods were carried out in accordance with relevant guidelines and regulations. As per CPRD (), no information that can identify a patient is ever sent to CPRD; CPRD never receives any patient identifiers from a general practitioner (GP) practice such as patient name, address, NHS number, full date of birth or medical notes; and because a patient cannot be identified from data a GP practice sends to CPRD, ISAC does not require the GP practice to seek a patient\u2019s consent to share data with CPRD.This study is based on data from the Clinical Practice Research Datalink (CPRD) obtained under license from the United Kingdom Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the National Health Service (NHS) as part of their care and support. The interpretation and conclusions contained in this report are those of the authors alone.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MR and OH are employees of the GSK group of companies (GSK). ASc, ASu, and SS were GSK employees at the time of the study. OH, ASc, and SS own GSK stocks or shares. DL, SG, NSL, and RD are salaried employees of Evidera, the consultancy company hired by GSK to perform this work. The authors declare no other financial or non-financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"330"}}